Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P27815

UPID:
PDE4A_HUMAN

ALTERNATIVE NAMES:
DPDE2; PDE46

ALTERNATIVE UPACC:
P27815; O75522; O76092; Q16255; Q16691; Q5DM53; Q6PMT2; Q8IVA7; Q8WUQ3; Q9H3H2

BACKGROUND:
cAMP-specific 3',5'-cyclic phosphodiesterase 4A, also referred to as DPDE2 and PDE46, is integral to the hydrolysis of 3',5'-cyclic AMP (cAMP), a key regulator of numerous vital physiological processes. This enzyme uniquely hydrolyzes cAMP efficiently, a function not affected by the presence of calcium, calmodulin, or cyclic GMP (cGMP), distinguishing it from other phosphodiesterases.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of cAMP-specific 3',5'-cyclic phosphodiesterase 4A unveils potential avenues for therapeutic intervention. Given its crucial role in the degradation of cAMP, targeting this protein could lead to innovative treatments by modulating signal transduction pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.